研究文章
模式的转移性雌激素受体阳性乳腺癌的进展:一个论点为当地治疗
|
|
整个队列 |
扩散的进展 |
有限的进展(< 3网站) |
| 整个队列 |
Oligoprogression |
Oligometastatic +进展 |
|
| 课程, |
195年 |
150年 |
45 |
28 |
18 |
|
| 课程类型的治疗,(%) |
|
|
|
|
|
| 芳香化酶抑制剂 |
77例(39%) |
58 (39%) |
19 (42%) |
13 (48%) |
6 (33%) |
| 人工智能+促性腺激素 |
29 (15%) |
23 (15%) |
6 (13%) |
2 (7%) |
4 (22%) |
| 人工智能+ everolimus |
13 (7%) |
11 (7%) |
2 (4%) |
2 (7%) |
0 (0%) |
| 人工智能+ fulvestrant |
14 (7%) |
9 (6%) |
5 (11%) |
4 (15%) |
1 (6%) |
| Fulvestrant |
38 (19%) |
30 (20% |
8 (18%) |
3 (11%) |
5 (28%) |
| 它莫西芬 |
22 (11%) |
17 (11%) |
5 (11%) |
3 (11%) |
2 (1%) |
| 其他 |
2 (1%) |
2 (1%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
| 额外的治疗,(%) |
|
|
|
|
|
| 二磷酸盐使用 |
102例(52%) |
77例(51%) |
25 (56%) |
19 (70%) |
6 (33%) |
| Her2治疗目标 |
37 (19%) |
19 (13%) |
16 (36%) |
7 (26%) |
9 (50%) |
|
平均时间进展
(每个) |
8(1 - 61)个月 |
8(1-38)个月 |
9(2 - 61)个月 |
12(2 - 30)个月 |
6个月(2 - 61) |
|
|
人工智能:芳香化酶抑制剂;促:促性腺激素释放激素。
|
